Payment overview · 2025
General Payments
$462.13
24 reported records · 7 companies
Healthcare provider profile · identity verified
Charles E Hill, PAC
Allopathic & Osteopathic Physicians|General Practice · PINEVILLE, WV · NPI 1851474845
Verified facts
What the public records show
CMS Open Payments records show Charles E Hill, PAC received $462.13 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $127.16 | 27.5% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $84.94 | 18.4% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $72.49 | 15.7% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $69.21 | 15.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.55 | 10.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.80 | 9.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.98 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $462.13 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.16 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $127.16 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $84.94 | 5 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $72.49 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $69.21 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 442 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 437 | 90 |
| Montelukast Sodium | Montelukast Sodium | 433 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 426 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 420 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 385 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 346 | 74 |
| Potassium Chloride | Potassium Chloride | 338 | 69 |
| Lisinopril | Lisinopril | 329 | 66 |
| Gabapentin | Gabapentin | 328 | 82 |
| Furosemide | Furosemide | 319 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 306 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 54 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 253 | 64 |
| Famotidine | Famotidine | 248 | 63 |
| Meloxicam | Meloxicam | 248 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 119 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 225 | 52 |
| Ibuprofen | Ibuprofen | 222 | 52 |
| Losartan Potassium | Losartan Potassium | 214 | 41 |
| Lorazepam | Lorazepam | 213 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 212 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 193 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 185 | 47 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 169 | 131 |
| Metformin Hcl | Metformin Hcl | 165 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 165 | 36 |
| Metformin Hcl Er | Metformin Hcl | 163 | 34 |
| Tramadol Hcl | Tramadol Hcl | 159 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 146 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 128 | 27 |
| Entresto | Sacubitril/Valsartan | 125 | 20 |
| Clonidine Hcl | Clonidine Hcl | 124 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 117 | 19 |
| Azithromycin | Azithromycin | 114 | 93 |
| Eliquis | Apixaban | 112 | 22 |
| Ozempic | Semaglutide | 112 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 31 |
| Trazodone Hcl | Trazodone Hcl | 107 | 24 |
| Simvastatin | Simvastatin | 104 | 22 |
| Glipizide Er | Glipizide | 103 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 24 |
| Methylprednisolone | Methylprednisolone | 99 | 72 |
| Allopurinol | Allopurinol | 96 | 19 |
| Alprazolam | Alprazolam | 96 | 17 |
| Carvedilol | Carvedilol | 91 | 24 |
| Ondansetron Odt | Ondansetron | 91 | 37 |
| Januvia | Sitagliptin Phosphate | 88 | 22 |
| Buspirone Hcl | Buspirone Hcl | 86 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 15 |
| Fluconazole | Fluconazole | 77 | 48 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 73 | 15 |
| Sertraline Hcl | Sertraline Hcl | 73 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 13 |
| Clonazepam | Clonazepam | 68 | 19 |
| Cefdinir | Cefdinir | 67 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 24 |
| Prednisone | Prednisone | 64 | 41 |
| Jardiance | Empagliflozin | 63 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 63 | 30 |
| Atenolol | Atenolol | 61 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Farxiga | Dapagliflozin Propanediol | 55 | 13 |
| Cephalexin | Cephalexin | 54 | 43 |
| Baclofen | Baclofen | 53 | 16 |
| Glimepiride | Glimepiride | 53 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 53 | 11 |
| Diazepam | Diazepam | 52 | 19 |
| Lovastatin | Lovastatin | 52 | 17 |
| Spironolactone | Spironolactone | 52 | 12 |
| Donepezil Hcl | Donepezil Hcl | 51 | suppressed |
| Ezetimibe | Ezetimibe | 51 | 15 |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | 13 |
| Amoxicillin | Amoxicillin | 49 | 38 |
| Bupropion Xl | Bupropion Hcl | 49 | suppressed |
| Fenofibrate | Fenofibrate | 49 | 11 |
| Finasteride | Finasteride | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | suppressed |
| Nystatin | Nystatin | 45 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 40 |
| Mirtazapine | Mirtazapine | 43 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | 12 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | 16 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Naproxen | Naproxen | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Nabumetone | Nabumetone | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Indomethacin | Indomethacin | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Dutasteride | Dutasteride | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Colchicine | Colchicine | 25 | 12 |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Irbesartan | Irbesartan | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $462.13 · 24 records | Novo Nordisk Inc | AIRSUPRA, LINZESS, Ohtuvayre, Ozempic, QULIPTA, Rybelsus, UBRELVY, VERQUVO, VOQUEZNA, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error